Position of the Transparency Council – Imjudo (tremelimumab)
At its meeting on 30 September 2024, the Transparency Council adopted position No. 101/2024 on the evaluation of the drug Imjudo (tremelimumab) within the framework of the drug program drug program “Treatment of patients with lung cancer (ICD-10 C34) and pleural mesothelioma (ICD-10 C45)”